By Colin Kellaher Merck & Co. on Tuesday said a Phase 3 study of its Keytruda cancer drug met the second of its dual primary endpoints as a perioperative…
Markets – MarketWatch
Merck: Phase 3 Keytruda Study Hits Second Goal in Non-Small Cell Lung Cancer Markets – MarketWatch
